Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining an Immune Checkpoint Inhibitor With SBRT or Hypo-fractionated RT in the Treatment of Stage I-III NSCLC: an Exploratory Study on Radiation Dose and Treatment Efficacy.

NCT05451173 is registered in ClinicalTrials.gov with Alexander Chi as lead sponsor.

NCT NCT05451173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05451173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining an Immune Checkpoint Inhibitor With SBRT or Hypo-fractionated RT in the Treatment of Stage I-III NSCLC: an Exploratory Study on Radiation Dose and Treatment Efficacy.
Lead sponsor
Alexander Chi
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 9, 2023
Completion date
December 31, 2025
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell carcinoma, non-small cell lung cancer, non-small cell lung cancer stage i, non-small cell lung cancer stage ii, non-small cell lung cancer stage iii